ArticleCureus2025
Complete Response in Salivary Duct Carcinoma Ex Pleomorphic Adenoma With Upfront Combination of Trastuzumab and Chemo-Hormonal Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolving Concepts in Salivary Duct Carcinoma: A Narrative Review.Oncology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salivary duct carcinoma (SDC) is one of the rarest malignancies. It can arise de novo or from pre-existing pleomorphic adenoma (carcinoma ex pleomorphic adenoma - CXPA) and can be very aggressive. Here, we present one such case of a 48-year-old male with relapsed, widely invasive SDC ex pleomorphic adenoma of the parotid that was locally advanced with intracranial extension that was refractory to chemo-radiation. Immunohistochemistry confirmed positivity for human epidermal growth factor receptor-2 (HER2) and androgen receptor (AR). He was started on a combination of trastuzumab, Combined Androgen Blockade (CAB) with leuprolide and bicalutamide, and docetaxel. Follow-up imaging at three months and nine months from treatment initiation demonstrated a complete response, ongoing at 17 months at follow-up. The upfront combination of anti-HER2 therapy, CAB, and chemotherapy resulted in a durable complete response in an aggressive disease. The result obtained from our experience provides valuable insight into the management of a rare and treatment-resistant entity, where large prospective studies without heterogeneity are not possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.